Axovant is accelerating the development of innovative gene therapy products that address serious neurological and neuromuscular diseases with significant unmet medical needs. We are currently studying gene therapy candidates for GM1 gangliosidosis, Tay-Sachs and Sandhoff diseases, and Parkinson’s disease in clinical trials and are working quickly to bring gene therapy candidates for other indications to patients in the clinic. We know that patients can’t wait, so neither will we.
Source
